121 related articles for article (PubMed ID: 26474663)
1. Antitumour benzothiazoles. Part 32: DNA adducts and double strand breaks correlate with activity; synthesis of 5F203 hydrogels for local delivery.
Stone EL; Citossi F; Singh R; Kaur B; Gaskell M; Farmer PB; Monks A; Hose C; Stevens MF; Leong CO; Stocks M; Kellam B; Marlow M; Bradshaw TD
Bioorg Med Chem; 2015 Nov; 23(21):6891-9. PubMed ID: 26474663
[TBL] [Abstract][Full Text] [Related]
2. Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1.
Wang K; Guengerich FP
Chem Res Toxicol; 2012 Aug; 25(8):1740-51. PubMed ID: 22734839
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines.
Bradshaw TD; Stone EL; Trapani V; Leong CO; Matthews CS; te Poele R; Stevens MF
Breast Cancer Res Treat; 2008 Jul; 110(1):57-68. PubMed ID: 17674193
[TBL] [Abstract][Full Text] [Related]
4. Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.
Leong CO; Gaskell M; Martin EA; Heydon RT; Farmer PB; Bibby MC; Cooper PA; Double JA; Bradshaw TD; Stevens MF
Br J Cancer; 2003 Feb; 88(3):470-7. PubMed ID: 12569393
[TBL] [Abstract][Full Text] [Related]
5. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate.
Bradshaw TD; Westwell AD
Curr Med Chem; 2004 Apr; 11(8):1009-21. PubMed ID: 15078163
[TBL] [Abstract][Full Text] [Related]
6. Self-Assembling Benzothiazole-Based Gelators: A Mechanistic Understanding of in Vitro Bioactivation and Gelation.
Citossi F; Smith T; Lee JB; Segal J; Gershkovich P; Stocks MJ; Bradshaw TD; Kellam B; Marlow M
Mol Pharm; 2018 Apr; 15(4):1578-1586. PubMed ID: 29502421
[TBL] [Abstract][Full Text] [Related]
7. Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery.
Breen AF; Scurr D; Cassioli ML; Wells G; Thomas NR; Zhang J; Turyanska L; Bradshaw TD
Int J Nanomedicine; 2019; 14():9525-9534. PubMed ID: 31824148
[TBL] [Abstract][Full Text] [Related]
8. The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds.
Bradshaw TD; Stevens MF; Westwell AD
Curr Med Chem; 2001 Feb; 8(2):203-10. PubMed ID: 11172675
[TBL] [Abstract][Full Text] [Related]
9. Antitumour benzothiazoles. Part 15: The synthesis and physico-chemical properties of 2-(4-aminophenyl)benzothiazole sulfamate salt derivatives.
Shi DF; Bradshaw TD; Chua MS; Westwell AD; Stevens MF
Bioorg Med Chem Lett; 2001 Apr; 11(8):1093-5. PubMed ID: 11327598
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445).
Bradshaw TD; Chua MS; Orr S; Matthews CS; Stevens MF
Br J Cancer; 2000 Jul; 83(2):270-7. PubMed ID: 10901382
[TBL] [Abstract][Full Text] [Related]
11. CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells.
Tan BS; Tiong KH; Muruhadas A; Randhawa N; Choo HL; Bradshaw TD; Stevens MF; Leong CO
Mol Cancer Ther; 2011 Oct; 10(10):1982-92. PubMed ID: 21831963
[TBL] [Abstract][Full Text] [Related]
12. 2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole is a ligand and shows species-specific partial agonism of the aryl hydrocarbon receptor.
Bazzi R; Bradshaw TD; Rowlands JC; Stevens MF; Bell DR
Toxicol Appl Pharmacol; 2009 May; 237(1):102-10. PubMed ID: 19265716
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of sensitivity to potent and selective antitumor 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F203) in ovarian cancer.
Callero MA; Luzzani GA; De Dios DO; Bradshaw TD; Perez AI
J Cell Biochem; 2013 Oct; 114(10):2392-404. PubMed ID: 23696052
[TBL] [Abstract][Full Text] [Related]
14. The antitumour activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole in human gastric cancer models is mediated by AhR signalling.
Wang Y; Liu Y; Tang T; Luo Y; Stevens MFG; Cheng X; Yang Y; Shi D; Zhang J; Bradshaw TD
J Cell Mol Med; 2020 Jan; 24(2):1750-1759. PubMed ID: 31876059
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells.
Brantley E; Antony S; Kohlhagen G; Meng L; Agama K; Stinson SF; Sausville EA; Pommier Y
Cancer Chemother Pharmacol; 2006 Jul; 58(1):62-72. PubMed ID: 16331501
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles.
Bradshaw TD; Chua MS; Browne HL; Trapani V; Sausville EA; Stevens MF
Br J Cancer; 2002 Apr; 86(8):1348-54. PubMed ID: 11953897
[TBL] [Abstract][Full Text] [Related]
17. Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells.
Brantley E; Trapani V; Alley MC; Hose CD; Bradshaw TD; Stevens MF; Sausville EA; Stinson SF
Drug Metab Dispos; 2004 Dec; 32(12):1392-401. PubMed ID: 15355884
[TBL] [Abstract][Full Text] [Related]
18. Antitumour benzothiazoles. Part 20: 3'-cyano and 3'-alkynyl-substituted 2-(4'-aminophenyl)benzothiazoles as new potent and selective analogues.
Hutchinson I; Bradshaw TD; Matthews CS; Stevens MF; Westwell AD
Bioorg Med Chem Lett; 2003 Feb; 13(3):471-4. PubMed ID: 12565953
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.
Bradshaw TD; Bibby MC; Double JA; Fichtner I; Cooper PA; Alley MC; Donohue S; Stinson SF; Tomaszewjski JE; Sausville EA; Stevens MF
Mol Cancer Ther; 2002 Feb; 1(4):239-46. PubMed ID: 12467219
[TBL] [Abstract][Full Text] [Related]
20. In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles.
Leong CO; Suggitt M; Swaine DJ; Bibby MC; Stevens MF; Bradshaw TD
Mol Cancer Ther; 2004 Dec; 3(12):1565-75. PubMed ID: 15634650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
